GUIDELINES FOR THE USE OF FRESH FROZEN PLASMA

REFERENCES

• The Sanguis Study Group. Use of blood products for elective surgery in 43 European hospitals. Transfus Med 1994;4:251–68.
   Web of Science ®Google Scholar
• Superior Health Council. Guidelines for the transfusion of fresh frozen plasma. Advisory Report no 8157. Brussels: Superior Health Council; 2007.
   Google Scholar
• Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of inva-sive procedures: an evidence-based review. Transfusion 2005;45:1413–25.
   PubMed Web of Science ®Google Scholar
• Williamson LM, Llewelyn CA, Fisher NC, et al. A randomised trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplan-tation. Transfusion 1999;39:1227–34.
   Google Scholar
• Holland LL, Brooks JP.Toward rational fresh frozen plasma trans-fusion: The effect of plasma transfusion on coagulation test results. Am] din Pathol 2006;126:133–9.
   PubMed Web of Science ®Google Scholar
• Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br] Haematol 2004;125:69–73.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab H, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006;46:1279–85.
   Web of Science ®Google Scholar
• Stanworth Si, Brunskill Si, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004;126:139–52.
   PubMed Web of Science ®Google Scholar
• Bickell WH, Wall MJ, Jr., Pepe PE, et al. 1994. Immediate versusdelayed fluid resuscitation for hypotensive patients with pen-etrating torso injuries. N EnglJ Med 1994;331:1105–9.
   PubMed Web of Science ®Google Scholar
• Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving mas-sive transfusions at a combat support hospital.] Trauma 2007;63:805–13.
   PubMed Web of Science ®Google Scholar
• Kasper SM, Giesecke T, Limpers P, Sabatowski R, Mehlhorn U, Diefenbach C. Failure of autologous fresh frozen plasma to re-duce blood loss and transfusion requirements in coronary artery bypass surgery. Anesthesiology 2001;95:81–6.
   PubMed Web of Science ®Google Scholar
• Makris M, Greaves M, Phillips WS, Kitchen, S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. ThrombHaemost 1997;77: 477–80.
   Google Scholar
• Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
   PubMed Web of Science ®Google Scholar
• Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Lancet 1996;348:229–32.
   PubMed Web of Science ®Google Scholar
• Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008;39:75–82.
   PubMed Web of Science ®Google Scholar
• Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003;43: 1322–9.
   PubMed Web of Science ®Google Scholar
• Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. TransfusApherSci 2006;35:5–17.
   Web of Science ®Google Scholar
• Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877–85.
   PubMed Web of Science ®Google Scholar
• Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new patho-gen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911–9.
   PubMed Web of Science ®Google Scholar
• Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826–31.
   PubMed Web of Science ®Google Scholar
• Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006;35:83–90.
   Web of Science ®Google Scholar
• Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma prepa-rations: correlation between composition and therapeutic ef-ficacy. Thromb Res 2002;107(Suppl 1):53–58.
   Google Scholar
• Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Cuff Opin Hematol 2004;11:346–50.
   Web of Science ®Google Scholar
• Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transf Med Rev 2008; 22:58–69.
   PubMed Web of Science ®Google Scholar
• Byrnes JJ, Moake JL, Klug P, Penman P. Effectiveness of the cryo-supernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura . Am] Hematol 1990;34:169–74.
   Web of Science ®Google Scholar
• Owens MR, Sweeney J D, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for throm-botic thrombocytopenic purpura . J Clin Apher 1995;10:178–82.
   PubMed Web of Science ®Google Scholar
• Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosu-pernatant as replacement fluid for plasma exchange in throm-botic thrombocytopenic purpura. Members of the Canadian Apheresis Group .BrJHaematol 1996;94:383–6.
   PubMed Web of Science ®Google Scholar
• Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult throm-botic thrombocytopenic purpura (TTP). ClinApher 200116: 19–22.
   Google Scholar
• Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. BrJ Haematol 2005;129:79–86.
   PubMed Web of Science ®Google Scholar
• de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma ex-change in patients with thrombotic thrombocytopenic purpura. BrJ Haematol 2001;114:721–3.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246–51.
   PubMed Web of Science ®Google Scholar
• Mintz PD, Neff A, MacKenzie M, et al. A randomised, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693–704.
   PubMed Web of Science ®Google Scholar
• Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006;20:273–82.
   PubMed Web of Science ®Google Scholar
• Hebert PC, Wells G, Blajchman MA, et al. A multicenter, ran-domised, controlled clinical trial of transfusion requirements in critical care.Transfusion Requirements in Critical Care Investiga-tors, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409–17.
   PubMed Web of Science ®Google Scholar
• Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med 2005;11:982–5.
   PubMed Web of Science ®Google Scholar
• Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006;313:92–4.
   PubMed Web of Science ®Google Scholar
• Eglin RP, Murphy WG. Beyond leukodepletion: removing infec-tious prions by filtration. Transfusion 2005;45:1836–8.
   Web of Science ®Google Scholar
• Agence francaise de sécurité sanitaire des produits de sante. Rapport annuel Hémovigilance 2003. Paris:Agence francaise de sécurité sanitaire des produits de sante; 2004.
   Google Scholar
• Agence fédérale des medicaments et produits de sante. Rapport annuel 2006 Hémovigilance. Reactions et incidents indésirables graves notifies par les hopitaux. Bruxelles: Agence fédérale des medicaments et produits de sante; 2007.
   Google Scholar